Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , May 12, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2022 , and provided an update on the progress of its clinical programs. Recent Achievements and Outlook Corporate Strategic Focus.
View HTML
Toggle Summary vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update
HIGH POINT, N.C. , March 29, 2022 /PRNewswire/ -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the fourth quarter and year ended December 31, 2021 , and provided an update on the progress of its clinical programs. "I am dedicated to the long-term growth and development
View HTML
Toggle Summary vTv Therapeutics Announces CEO Transition
HIGH POINT, N.C. , March 3, 2022 /PRNewswire/ --  vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes, today announced that the Company has appointed Rich Nelson as Acting Chief Executive
View HTML
Toggle Summary vTv Therapeutics Shares Updated Corporate Presentation
HIGH POINT, N.C. , Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral
View HTML
Toggle Summary vTv Therapeutics Announces Restructuring to Prioritize its Lead Program and Focus Operations
-Workforce reduction of 65% -Prioritization of lead program TTP399, a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients HIGH POINT, N.C. , Dec. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Nov. 09, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2021 , and provided an update on the progress of its clinical programs. “We plan to refocus vTv’s strategy on TTP399.  TTP399 is unique
View HTML
Toggle Summary vTv Therapeutics Announces Deepa Prasad as New President and CEO
HIGH POINT, N.C. , Oct. 20, 2021 /PRNewswire/ --  vTv Therapeutics Inc.  (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that Deepa Prasad will lead the company as President and
View HTML
Toggle Summary vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
Study achieved primary endpoint of non-inferiority on measurement of key blood ketone levels Patients taking TTP399 reported no events of hypoglycemia, while four events of hypoglycemia were reported in the placebo arm Start-up activities for Phase 3 program ongoing with trials expected to begin in
View HTML
Toggle Summary vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support advancement of HPP737 into Phase 2 in moderate to severe psoriasis. Successful pre-IND meeting with U.S.
View HTML
Toggle Summary vTv Therapeutics Announces 2021 Second Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2021 , and provided an update on the progress of its clinical programs. “We held our first, highly-productive meeting with the FDA
View HTML